Atrium Therapeutics, Inc. (RNA) Stock Price & Analysis
Atrium Therapeutics, Inc. (RNA) closed at USD 7.82 on Thursday, October 15, 2026, up 1.82% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.68; the Oct 15, 2026 session ranged USD 7.65–7.87 on volume of 131,235 shares. Market capitalization is $133.77M, with a 52-week range of USD 7.54–16.77 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RNA.md
Key facts (RNA)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 25 (range 25–25).
- Total return with dividends: 1Y -47.0% vs S&P 500 +18.1%; 5Y -47.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.67, revenue estimate $11.3M.
Analysts (RNA)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 25 (low 25, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-08-06 | HC Wainwright & Co. | Initiated | Buy | $25 |
| 2026-06-18 | Cantor Fitzgerald | Initiated | Overweight | $25 |
Total return (dividends reinvested) (RNA)
| 1Y (from 2026-02-27) | 5Y (from 2026-02-23) | |
|---|---|---|
| Total return | -47.0% | -47.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 54.5% | 56.0% |
| Max drawdown | -53.6% (Mar 2026→Oct 2026) | -47.2% (Mar 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 7.82 |
|---|---|
| Change | ▲ 1.82% (up) |
| Previous Close | USD 7.68 |
| Open | USD 7.75 |
| Day Range | USD 7.65 – 7.87 |
| 52-Week Range | USD 7.54 – 16.77 |
| Volume | 131,235 shares |
| Market Cap | $133.77M |
| Exchange | NMS |
Technical Analysis (RNA)
Nexqual's technical model rates RNA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.63 (oversold) |
| vs SMA50 | Below (USD 10.77) |
| MACD | -0.8 (negative) |
Analyst Ratings (RNA)
Wall Street analysts rate RNA "Buy" based on 4 analysts, with a mean price target of USD 25 (range USD 25–25), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 25 |
| High Target | USD 25 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (RNA)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $11.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.18 vs est -0.64 ▼ miss |
| 2026-03-31 | USD -0.97 vs est -1.05 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (RNA)
| Total Revenue | $35.84M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -21.90% |
| Gross Margin | -56.37% |
| Operating Margin | -752.93% |
| Profit Margin | -184.15% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.73 |
| Total Cash | $263.90M |
| Total Debt | $1.68M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (RNA)
Nexqual rates Atrium Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Critical — Revenue -22% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $264M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$53M (TTM) |
| Efficiency | Mixed — No data |
Ownership (RNA)
| Insider Ownership | +4.16% |
|---|---|
| Institutional Ownership | +84.87% |
| Shares Outstanding | 17.11M |
| Float | 15.04M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (RNA)
Atrium Therapeutics, Inc. is led by Kathleen P. Gallagher (age 44), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | Kathleen P. Gallagher (age 44) |
|---|---|
| Chief Financial Officer | Brendan Winslow (age 37) |
| Chief Scientific Officer | Husam Younis Ph.D., Pharm.D. (age 51) |
| Chief Strategy Officer | Rocio Martin Hoyos (age 42) |
Major Backers & Investors (RNA)
Notable institutional backers of Atrium Therapeutics, Inc. include Sessa Capital IM, L.P., Price (T.Rowe) Associates Inc, CRCM LP, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sessa Capital IM, L.P. | 8.77% |
| Price (T.Rowe) Associates Inc | 8.61% |
| CRCM LP | 7.5% |
| T. Rowe Price | 5.9% |
| TIG Advisors, LLC | 3.28% |
| Two Sigma Investments, LP | 2.02% |
| Goldman Sachs | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.18% |
| Vanguard Group | 8.4% |
| Geode Capital | 2.26% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt